PERSPECTIVES IN CONTRAST

The subcutaneous implantable cardioverter-defibrillator should be reserved for niche indications

Yang Yang, MD, Ulrika Birgersdotter-Green, MD, FHRS

From the Department of Cardiac Electrophysiology, University of California San Diego, San Diego, California.

Since the introduction of the first implantable cardioverter-defibrillator (ICD) in 1980, ICDs have undergone significant improvements to become the pillar of sudden death prevention today. The first device consisted of a 250-g abdominal generator with a surgically applied pericardial patch.1 Over time, the generator decreased to one-fifth of its original size, and the pericardial patch was replaced by transvenous leads with integrated defibrillation coils. However, for patients with impaired venous access or children with congenital heart disease, epicardial systems remained their only option until the development of the subcutaneous implantable cardioverter-defibrillator (S-ICD).

The S-ICD borrows many design elements from the transvenous system and is composed of an extrathoracic lead and pulse generator. Its subcutaneous leads were touted to have increased longevity and decreased infectious risk. Whereas lead-related infective endocarditis has been reported in 22% of all ICD-related infections, the rate of systemic infection with the S-ICD is extremely low and has only been described in case reports.2,3

As the S-ICD passes its first decade in clinical practice, many electrophysiologists have started to ask whether the S-ICD should be considered as a first option for all patients. Two recently published randomized trials (PRAETORIAN [Prospective Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy] and ATLAS [Avoid Transvenous Leads in Appro- priate Subjects]) compared the S-ICD to the TV-ICD head to head.4,5

The subcutaneous design comes with tradeoffs that cannot be ignored (Table 1). Because of the lack of endocardial pacing components, patients with long-term pacing needs are ineligible for the S-ICD.6 The reliance on far-field sensing hampers appropriate arrhythmia detection. The extrathoracic position increases defibrillation thresholds (DFTs),7,8 requiring a larger battery in the S-ICD capable of delivering an 80-J charge and limiting the lifespan of the device. All these factors relegate the S-ICD to the realm of a niche device.

Sensing limitations

With the absence of any endocardial components, the S-ICD must solely rely on subcutaneous electrocardiography for arrhythmia detection. Sensing electrodes on distal and proximal portions of the subcutaneous lead and the generator constitute the 3 possible poles for the sensing vectors. All 3 vectors span a large portion of the precordium and provide far-field sensing not only of the QRS complex but also of the P and T waves as a result of the larger size of the antenna. Therefore, algorithms for arrhythmia detection in the S-ICD have the unique challenge of separating the QRS complex from other cardiac and extracardiac signals before other criteria can be applied.

For optimization of signal-to-noise ratios, all S-ICD candidates must be screened before implantation. Any vector with a small QRS-to-T-wave ratio is rejected because of concern for T-wave oversensing. In addition, vectors with absolute QRS amplitudes above or below the threshold are rejected. Up to 10% of patients can fail this screening process in all 3 vectors, and up to 37% of passing vectors may fail upon rescreening.9,10 This severely restricts the eligible patient population. Furthermore, the proportion shrinks dramatically when looking at patients who benefit the most from an extracardiac device. Young patients with channelopathies and inherited cardiomyopathies often have abnormal repolarization with exaggerated T-wave amplitudes. In patients with arrhythmogenic right ventricular cardiomyopathy, up to 37% failed S-ICD screening; and in patients with hypertrophic cardiomyopathy, 48% failed screening in ≥2 vectors.11

Passing the screening process does not prevent sensing issues postimplantation. Far-field sensing issues with the S-ICD led to a higher rate of inappropriate shocks (IAS) in the initial S-ICD compared to TV-ICDs, with T-wave oversensing being the major cause. Although T waves may pass screening during sinus rhythm, with conduction abnormalities, frequent premature ventricular contractions, or slow ventricular tachycardia (VT), abnormal repolarization can lead to amplified T waves and oversensing. Similarly,
conduction system abnormalities can prolong the QRS complex and lead to double counting. In rare cases, atrial hypertrophy has also led to large p waves being miscounted. Common issues with S-ICD sensing are shown in Figure 1. With the longer antenna used for subcutaneous electrocardiography, electromagnetic interference becomes more prominent. Air entrapped in the generator pocket can mimic ventricular fibrillation (VF), with use of a transcutaneous electrical nerve stimulation unit responsible for 25% of IAS in the ATLAS trial. The S-ICD attempts to exclude extracardiac signals using an algorithm based on frequency and slew rate analysis. However, discounting low-amplitude, high-frequency signals may delay or inappropriately withheld therapies in VF. Up to 14% of patients at the time of DFT testing had significant delays to time of therapy, and up to 4% had noise oversensing leading to absence of appropriate VF detection.

Valiant attempts have been made to accurately identify arrhythmias through the SMART Pass algorithm, but it is not a cure-all. Even with appropriate programming, S-ICD sensing still falls short. In the latest clinical trials comparing S-ICD vs TV-ICD, there still is an alarming trend toward higher IAS despite the widespread use of SMART Pass. Patients with S-ICDs had 6.4% IAS compared to 2.8% in the TV-ICD group (odds ratio 2.38; 95% confidence interval 0.96–5.90) during mean 2.5 years of follow-up in the ATLAS trial. Although failing to reach statistical significance, the trend of higher IAS with the S-ICD is supported by a multitude of real-world registries. An Italian S-ICD registry reported an IAS rate of 9.4% in 2 years, similar to rates reported worldwide in the EFFORTLESS (Evaluation of Factors Impacting Clinical Outcome and Cost Effectiveness of the S-ICD) trial (11.7% in 3 years). Given that IAS are psychologically harmful and lead to increased health care utilization, the S-ICD cannot be considered as a first option until any issues are addressed.

### Table 1

| Advantages | Disadvantages |
|------------|---------------|
| Able to implant in patients with congenital heart disease | Reliance on far-field sensing leads to issues separating QRS complex from cardiac and noncardiac signals |
| Able to implant in patients who lack vascular access | Lack of endocardial pacing leads to inability to deliver ATP, atrial pacing, CRT, or conduction system pacing |
| Lack of transvenous leads lowers risk of infection and thrombosis for patients with risk of infection or thrombosis | All extrathoracic components require careful implant technique to avoid adipose tissue acting as insulator for defibrillation |

Of the S-ICD) trial (11.7% in 3 years). The lack of antitachycardia pacing (ATP) leaves a gaping hole in the electrophysiologist’s arsenal and severely limits widespread adoption of the S-ICD. In PRAETORIAN, 50% of all VT episodes in TV-ICD patients were terminated successfully with ATP. In other real-world registries, ATP can terminate up to 87% of VTs <200 bpm and 62% of fast VTs between 200 and 250 bpm. ICD shocks undoubtedly are effective in terminating life-threatening arrhythmias, but we know from decades of experience that ATP can provide a painless and trauma-free option to terminate arrhythmias. To take away that option would be very difficult.

Even if we were to make that decision, experience tells us a significant portion of patients who qualify for an ICD without pacing needs eventually will develop such needs. Trials of primary prevention ICD patients show 10% will develop pacing needs in 5 years. Contemporary observational studies hint this number may be even higher in the short term. In an observational study of patients with a single-chamber ICD over 2 years, 6.7% required >5% pacing when programmed at VVI 40 bpm. Unfortunate
patients who undergo S-ICD implantation and then develop pacing needs must undergo an additional procedure with either a transvenous pacemaker or a leadless pacemaker, thus incurring the cost and risk of an additional procedure. If a transvenous pacing system is implanted, all advantages of an extravascular system are lost. Trials are underway for a seemingly elegant solution to the problem—implantation of a leadless pacing system capable of communicating with the S-ICD to deliver ATP. However, the proposed solution still would not be able to provide atrial pacing, CRT, or conduction system pacing. It also comes with the additional cost and complexity of 2 independent devices requiring 2 separate procedures at the time of replacement.

Uncertainty with defibrillation success
Successful defibrillation therapy requires the maximum amount of current to cross the myocardium. The positions of the shock coil and generator, as well as their surrounding tissues, can drastically affect the flow of current between them and are crucial to terminating VT/VF.

In the TV-ICD, the shock coil is embedded in the right ventricle and is surrounded by either myocardium or blood, both low-impedance tissues. In the S-ICD, however, the shock coil sits parasternally and can be in contact with either muscle (low impedance) or adipose tissue (high impedance). Any adipose tissue around the coil would dramatically increase DFTs. In addition, because the S-ICD shock coil sits in an extrathoracic anterior position, any anterior shift of the generator past the midline would dramatically reduce the amount of myocardium crossed by the shock vector. Therefore, minimizing adipose tissue between the lead and sternum, as well as ensuring a posterior location of the generator, are crucial predictors of successful defibrillation.

Not surprisingly, obese patients pose significant challenges for S-ICD implantation, with increased body mass index being a good predictor of DFT failure at the time of implantation. In the United States, where the local prevalence of obesity can be >40%, the challenges are clear. Additionally, DFTs may not be stable over time, as 20% of patients fail repeat DFT testing at the time of S-ICD generator change.

Improvements in TV-ICDs
Along with the technical innovations of the S-ICD, TV-ICDs have continued to improve with regard to battery and lead longevity. Previous-generation lithium silver vanadium oxide batteries had nonlinear discharge curves and variable internal cell impedances leading to unpredictable replacement intervals and variable capacitor charge times. Newer models with manganese dioxide can maintain a high voltage over longer periods of time and stable internal impedances. This allows new devices to use 90% of capacity rather than 70% in the older models. Improved battery technology has increased the average service life of TV-ICDs significantly. The longer battery life of single-chamber TV-ICDs (average 8 years) compared with S-ICDs (average 5 years) means fewer procedures over the lifetime of the patient, thus reducing costs and procedure-related morbidity.

Historically, annual failure rates for defibrillation leads are estimated to be 2.7% per year, reaching about 20% in 10-year-old leads. This includes notable failures such as the Medtronic Fidelis and St. Jude Medical Riata leads, with failure rates of 4.8% per year and their subsequent recalls. Lessons from these failures have led to improvements in lead longevity. Short- and medium-term follow-up studies since the recalls have shown improved survival of defibrillation leads. In comparison, the first-generation S-ICD leads underwent a U.S. Food & Drug Administration class I recall due to unexpected lead fracture, with an estimated 0.2% annual estimated failure rate. One meta-analysis showed that first-generation S-ICD leads are no more durable than contemporary TV-ICD leads.

Increased costs
Although the S-ICD has been commercially available for more than a decade, costs in some locales still pale in comparison to the costs of TV-ICDs. In Europe, the S-ICD can cost between 3 to 7 times more than a single-chamber TV-ICD. This combined with a notably shorter battery life (5 years for the S-ICD vs 8 years for the TV-ICD) can lead to dramatically higher lifetime costs for an S-ICD implant. The proposed leadless pacing component for delivery of ATP would be another costly addition to an already expensive system.
Conclusion
Although the S-ICD is a valuable tool, we must recognize its limitations and use it appropriately. Just as the first ICD in 1980 was a revolutionary device with many limitations, the S-ICD certainly has room for improvement. The lack of permanent pacing for ATP, atrial pacing, CRT, and conduction system pacing; the difficulties with arrhythmia detection with far-field sensing; as well as the uncertainty of DFTs over time are problems with the S-ICD that must be solved before the device can be widely adopted. The combination of a leadless pacing system in communication with the S-ICD is undergoing clinical trials that would address concerns about the lack of ATP and bradycardia support. Meanwhile, efforts are being made to identify patients at risk for high DFTs. We look forward to the day when subcutaneous ICD systems can become the first option for our patients, but we are not there yet.

Funding Sources: The authors have no funding sources to disclose.

Disclosures: The authors have no conflicts to disclose.

Authorship: All authors attest they meet the current ICMJE criteria for authorship.

Disclaimer: Given her role as Associate Editor, Ulrika Birgersdotter-Green had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Editors Dennis H. Lau and Jeanne E. Poole.

References
1. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322–324.
2. Le KY, Sohail MR, Friedman PA, et al. Clinical predictors of cardiovascular implantable electronic device-related infective endocarditis. Pacing Clin Electrophysiol 2011;34:450–459.
3. Looser PM, Saleh L, Thomas G, Cheung JW. Systemic infection due to subcutaneous implantable cardioverter-defibrillator implantation: importance of early recognition and treatment of device pocket-related complications. HeartRhythm Case Rep 2016;3:40–42.
4. Knops RE, Olde Nordkamp LRA, Delnoy P-PHM, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med 2020;383:526–536.
5. Healey JS. Subcutaneous versus transvenous defibrillators: the ATLAS trial. Heart Rhythm Society. 2022. Late-Breaking Clinical Trials Session—LB-733 Randomized Clinical Trials. Heart Rhythm Society 2022 Annual Meeting, San Francisco, California, April 29–May 1, 2022.
6. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018;72:e91–e220.
7. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010;363:36–44.
8. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable cardioverter-defibrillator. Circulation 2013;128:944–953.
9. Conte G, Kawabata M, de Asmundis C, et al. High rate of subcutaneous implantable cardioverter-defibrillator: N Engl J Med 2010;363:36–44.
10. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable cardioverter-defibrillator. Circulation 2013;128:944–953.
11. Conte G, Kawabata M, de Asmundis C, et al. High rate of subcutaneous implantable cardioverter-defibrillator sensing screening failure in patients with Brugada syndrome: a comparison with other inherited primary arrhythmia syndromes. Europace 2018;20:1188–1193.
12. Wiles BM, Morgan JM, Allavatam V, ElRafei M, Roberts PR. S-ICD screening revisited: do passing vectors sometimes fail? Pacing Clin Electrophysiol 2022;45:182–187.
13. Srinivasan NT, Patel KH, Qamar K, et al. Disease severity and exercise testing reduce subcutaneous implantable cardioverter-defibrillator left sternal ECG screening success in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2017;10:e004801.
14. Omura A, Onuki T, Mase H, Kurata M, Wakasuki D, Suzuki H. A case of frequent and inappropriate shock with a subcutaneous implantable cardioverter defibrillator triggered by newly developed complete right bundle branch block. HeartRhythm Case Reports 2022;8:606–609.
15. Leventopoulos G, Papageorgiou A, Perperis A, Koros R, Tsigias G, Davloupos P. A potentially avertable cause of inappropriate shock in a patient with subcutaneous implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2022;45:893–895.
16. Ali H, Lupo P, Foresti S, et al. Air entrapment as a potential cause of early subcutaneous implantable cardioverter-defibrillator malfunction: a systematic review of the literature. Europace 2020;22:2560–2565.
17. le Polain de Waroux JB, Ploux S, Mondoly P, et al. Defibrillation testing is mandatory in patients with subcutaneous implantable cardioverter-defibrillator to confirm appropriate ventricular fibrillation detection. Heart Rhythm 2018;15:642–650.
18. Theuns DAMJ, Brouwer TF, Jones PW, et al. Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm 2018;15:1515–1522.
19. Guilleta S, Gasperetti A, Schiavone M, et al. Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter-defibrillators: a propensity-matched analysis from a multicenter European registry. Heart Rhythm 2019;16:1109–1115.
20. Boersma L, Barr C, Knops R, et al. Implant and midterm outcomes of the subcutaneous implantable cardioverter-defibrillator: the EFFORTLESS study. J Am Coll Cardiol 2017;70:830–841.
21. van Rees JB, Borleffs CJW, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011;57:556–562.
22. Jukema JW, Timal RJ, Rotman JI, et al. Prophylactic use of implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients. Circulation 2019;139:2628–2638.
23. Bansal N, Szpor A, Reynolds K, et al. Long-term outcomes associated with implantable cardioverter defibrillator in adults with chronic kidney disease. JAMA Intern Med 2018;178:390–398.
24. Friedman DJ, Singh JP, Curtis JP, et al. Comparative effectiveness of CRT-D versus defibrillator alone in HF patients with moderate-to-severe chronic kidney disease. J Am Coll Cardiol 2015;66:2618–2629.
25. Sweeney MO, Shersesse L, DeGroot PJ, Watjen MS, Wilkoff BL. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2010;7:353–360.
26. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.
27. Kalantar S, Bao H, Jones PW, et al. Abstract 19187: Predictors of right ventricular pacing in ICD recipients without baseline pacing needs. Circulation 2017;136:A19187–A19187.
28. Heist EK, Belalcazar A, Stahl W, Brouwer TF, Knops RE. Determinants of subcutaneous implantable cardioverter-defibrillator efficacy: a computer modeling study. JACC Clin Electrophysiol 2017;3:405–414.
29. Quast A-FBE, Baalmann SWE, Brouwer TF, et al. A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: the PRAETORIAN score. Heart Rhythm 2019;16:403–410.
30. Frankel DS, Burke MC, Callans DJ, Strivland TM, Duffy E, Epstein AE. Impact of body mass index on safety and efficacy of the subcutaneous implantable cardioverter–defibrillator. JACC Clin Electrophysiol 2018;4:652–659.
31. Rudic B, Tülemen E, Fastnacht F, Akin I, Borggreve M, Kuschky J. Defibrillation failure in patients undergoing replacement of subcutaneous defibrillator pulse generator. Heart Rhythm 2020;17:435–459.
32. Poli S, Boriani G, Zecchin M, et al. Favorable trend of implantable cardioverter–defibrillator service life in a large single-nation population: insights from 10-year analysis of the Italian Implantable Cardioverter-Defibrillator Registry. J Am Heart Assoc 2019;8:e012759.
33. Boriani G, Merino J, Wright DJ, Gadler F, Schaar B, Landolina M. Battery longevity of implantable cardioverter–defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA. Europace 2018;20:1882–1897.
34. Quast A-FBE, van Dijk VF, Yap S-C, et al. Six-year follow-up of the initial Dutch subcutaneous implantable cardioverter-defibrillator cohort: long-term
complications, replacements, and battery longevity. J Cardiovasc Electrophysiol 2018;29:1010–1016.
33. Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation 2007;115:2474–2480.
34. Rordorf R, Poggio L, Savastano S, et al. Failure of implantable cardioverter-defibrillator leads: a matter of lead size? Heart Rhythm 2013;10:184–190.
35. Mori H, Kato R, Ikeda Y, et al. Transvenous lead performance of implantable cardioverter-defibrillators and pacemakers. Pacing Clin Electrophysiol 2021; 44:481–489.
36. Resnic FS, Majithia A, Dhruva SS, et al. Active surveillance of the implantable cardioverter-defibrillator registry for defibrillator lead failures. Circ Cardiovasc Qual Outcomes 2020;13:e006105.
37. U.S. Food & Drug Administration. Boston Scientific Corporation Recalls EMBLEM S-ICD (Subcutaneous Implantable Cardioverter Defibrillator) System Due to Risk of Short-Circuit. February 19, 2021. https://www.fda.gov/medical-devices/medical-device-recalls/boston-scientific-corporation-recalls-emblem-s-icd-subcutaneous-implantable-cardioverter. Accessed August 10, 2022.
38. Grabowski M, Gawalko M, Michalak M, et al. Initial experience with the subcutaneous implantable cardioverter-defibrillator with the real costs of hospitalization analysis in a single Polish center. Cardiol J 2019; 26:360–367.
39. Cappelli S, Olaru A, De Maria E. The subcutaneous defibrillator: who stands to benefit. March 4, 2014. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-12/The-subcutaneous-defibrillator-who-stands-to-benefit. Accessed August 1, 2022.